EP0808166A1 - Arzneimittel zur behandlung von obsessiv-impulsiven erkrankungen wie schlafsapnoe, sexualfunktionsstörungen, erbrechen und reisekrankheit - Google Patents

Arzneimittel zur behandlung von obsessiv-impulsiven erkrankungen wie schlafsapnoe, sexualfunktionsstörungen, erbrechen und reisekrankheit

Info

Publication number
EP0808166A1
EP0808166A1 EP96944029A EP96944029A EP0808166A1 EP 0808166 A1 EP0808166 A1 EP 0808166A1 EP 96944029 A EP96944029 A EP 96944029A EP 96944029 A EP96944029 A EP 96944029A EP 0808166 A1 EP0808166 A1 EP 0808166A1
Authority
EP
European Patent Office
Prior art keywords
butyl
piperazinyl
pyrimidinyl
pyrazole
imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96944029A
Other languages
English (en)
French (fr)
Inventor
Jordi Frigola-Constansa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of EP0808166A1 publication Critical patent/EP0808166A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of 1- ⁇ 4- [4-aryl (or heteroaryl) -1-piperazinyl] -butyl ⁇ - 1-H-azole derivatives as well as their physiologically acceptable salts, for the manufacture of medicaments for the treatment of obsessive-compulsive disorder, sleep apnea, sexual dysfunction, Pemesis and motion sickness.
  • the aryl (or heteroaryl) - piperazinyl-butyl-azole derivatives show anti-obsessive activity, preventive of sleep apnea, which facilitates sexual, anti-magnetic and anti-nausea behavior and therefore they are useful in therapy for the prevention and treatment of obsessive-compulsive disorder, sleep apnea, sexual dysfunction and nausea and vomiting, in particular induced by chemotherapy and / or cytotoxic radiotherapy (s) or movement.
  • the compounds are intended for preventive or curative treatments in humans and in animals for depression, obsessive compulsive disorders, sleep apnea, sexual dysfunctions, emesis and motion sickness.
  • Ar represents an aromatic radical, nitrogenous or not, chosen from differently substituted aryls, 2-pyrimidine differently substituted, and 3- (1, 2-benzisothiazole),
  • Z1 represents a nitrogen atom or a substituted or unsubstituted carbon atom, which can be represented by: CR 1 ,
  • Z2 represents a nitrogen atom or a substituted or unsubstituted carbon atom, which can be represented by: CR 2 ,
  • Z4 represents a nitrogen atom or a substituted or unsubstituted carbon atom, which can be represented by: CR 4 ,
  • R 1 , R 2 , R 3 and R 4 identical or different, which can also form part of another cycle, aromatic or not, represent a hydrogen atom, a halogen, a lower alkyl radical, a nitro radical, a hydroxy radical, an alkoxy radical, a cyano radical, a hydroxycarbonyl radical, an alkoxycarbonyl radical, an aryl or substituted aryl radical, a sulfonic radical, a sulfonamido radical, an aminocarbonyl radical, substituted or not on the amino group, an amino radical or substituted amino,
  • Ar represents a differently substituted aryl, it is preferably a radical of formula
  • alkyl is understood to mean, according to the invention, lower alkyls, preferably C 1 -C 6 , linear or branched, optionally unsaturated, in particular methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl radicals and their different isomers. This definition also applies to the alkyl residues of the alkoxy.
  • halogen is meant according to the present invention preferably fluorine, chlorine, bromine or iodine.
  • aryl is understood in particular according to the invention an aromatic or heteroaromatic radical, in particular chosen from the radicals phenyl, naphthyl, anthryl, phenanthryl, pyridyl, pyrimidyl, etc., preferably phenyl, optionally substituted, in particular by one or more radicals selected from halogens, lower alkyl radicals, nitro, hydroxy, alkoxy, cyano, hydroxycarbonyl, alkoxycarbonyl , aryl or substituted aryl, sulfonic, sulfonamido, aminocarbonyl, substituted or not on the amino, amino or substituted amino group.
  • aromatic or heteroaromatic radical in particular chosen from the radicals phenyl, naphthyl, anthryl, phenanthryl, pyridyl, pyrimidyl, etc., preferably phenyl, optionally substituted, in particular by one or more radicals selected from halogens, lower
  • the substituents of the amino group are in particular alkyl or aryl radicals.
  • therapeutically acceptable salts is meant the usual salts of addition of organic or inorganic acids, such as hydrochlorides, dihydrochlorides, mesylates or tosylates.
  • serotonin (5-HT) is involved in the pathophysiology of affective disorders
  • pharmacological stimulation paradigms have been widely used to determine the "in vivo" dynamics of serotonin function in obsessive disorder compulsive, among others.
  • mice are placed in the illuminated compartment which becomes aversive to them and causes them a state of anxiety. This causes a flight response to the dark compartment, which may be associated with obsessive compulsive behavior.
  • the results obtained demonstrate that the lesopitron, at all the doses tested, delays the onset of obsessive-compulsive behavior of movement to the dark zone because the latency time clearly increases.
  • Sleep apnea includes a series of disorders of different magnitudes. Sleep apnea is classified as obstructive, central or mixed, depending on the presence or absence of respiratory effort during periods when the air flow is stopped. Obstructive and mixed apneas are the most frequent. They present with obstructive sleep apnea syndrome, in which recurrent and sporadic collapse of the upper respiratory tract is observed during sleep. If the collapse is complete, there is no air flow through the nose and mouth, and breathing stops. The usual result is a partial awakening of sleep and a return to normal breathing. In many cases the patient does not remember these episodes of apnea, but he feels tired and sleepy during the day, for no apparent reason. These episodes of recurrent apnea with hypoxemia and fragmented sleep can lead to serious neurological and cardiac consequences.
  • the rat electroencephalographic sleep study demonstrated that the 5 mg / kg lesopitron significantly increases the latency of sleep, at the same time as it decreases the total sleep time, that is, it increases waking time.
  • lesopitron can be a respiratory stimulant with persistent effects during sleep. It is therefore indicated for the treatment of sleep apnea.
  • the etiology of sexual dysfunction may include psychological factors, interpersonal and situational reasons, physical factors and, also, side effects of pharmacological agents. Since sexual dysfunction can be from a wide variety of these underlying causes, which can range from purely psychogenic to completely physical, it would be unrealistic to hope that only one treatment modality could become effective in any case. In usual clinical practice, sexual dysfunction is treated by determining the underlying causes and treating them when possible. In many cases the identification of the underlying causes of male and female sexual dysfunction is very complex, or even cannot be determined with certainty. The psychopharmacological treatment of sexual dysfunction is currently in its infancy. The use of drugs for the treatment of sexual dysfunction has had little success, which is evidenced by the absence of a widely accepted and recognized treatment for this use.
  • the results obtained with the lesopitron demonstrate the activity of the product by facilitating the sexual behavior of the rats.
  • the compounds of the invention have been studied as to their effects on emesis in ferrets according to a method described by Costall et al. (Neuropharmacology, 1986, 25, 9S9-961).
  • Ferrets of both sexes were individually conditioned at 21 ⁇ 1 ° C and fed normally. They were then administered the compound of Example 32 or a vehicle subcutaneously as a pretreatment 15 minutes before administration of cisplatin (10 mg / kg i.v. by way of a fixed jugular cannula). The animals were observed at the start of emesis, and after, for 240 minutes. Emesis was characterized by rhythmic abdominal contractions, either associated with the expulsion of solid or liquid matter (i.e. vomiting), or not associated with the passage of material through the mouth (nausea). The number of episodes and nausea or vomiting were recorded.
  • the compound of Example 32 is capable of antagonizing the emesis induced by cisplatin ( Figure 1).
  • FIG. 1 The compound of Example 32 is capable of antagonizing the emesis induced by cisplatin in the ferret.
  • the animals were observed for 240 minutes.
  • a significant difference compared to V is indicated sP ⁇ 0.05 (Mann-Whitney U test).
  • the administration dose is of course a function of the severity of the condition to be treated. It will generally be between about 5 and about 100 mg / day.
  • the derivatives of the invention will, for example, be administered in the form of tablets, capsules, or else intravenously. Two specific dosage forms will be indicated below, by way of examples.
  • the present invention extends to the application of these compounds as medicaments, to the pharmaceutical compositions containing them and to their use for the manufacture of medicaments intended for the treatment of obsessive-compulsive disorder, sleep apnea, sexual dysfunction, emesis and motion sickness.
  • the manufacture of antiobsessive agents preventive of sleep apnea, which facilitate sexual behavior, antiemetic and anti-nausea.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP96944029A 1995-12-12 1996-12-11 Arzneimittel zur behandlung von obsessiv-impulsiven erkrankungen wie schlafsapnoe, sexualfunktionsstörungen, erbrechen und reisekrankheit Withdrawn EP0808166A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9514690A FR2742052B1 (fr) 1995-12-12 1995-12-12 Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
FR9514690 1995-12-12
PCT/EP1996/005736 WO1997021439A1 (fr) 1995-12-12 1996-12-11 Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports

Publications (1)

Publication Number Publication Date
EP0808166A1 true EP0808166A1 (de) 1997-11-26

Family

ID=9485400

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96944029A Withdrawn EP0808166A1 (de) 1995-12-12 1996-12-11 Arzneimittel zur behandlung von obsessiv-impulsiven erkrankungen wie schlafsapnoe, sexualfunktionsstörungen, erbrechen und reisekrankheit

Country Status (16)

Country Link
EP (1) EP0808166A1 (de)
JP (1) JPH11501051A (de)
CN (1) CN1177297A (de)
AR (1) AR004378A1 (de)
AU (1) AU716665B2 (de)
CA (1) CA2211161A1 (de)
CZ (1) CZ255197A3 (de)
ES (1) ES2134709B1 (de)
FR (1) FR2742052B1 (de)
HU (1) HUP9800198A2 (de)
IL (1) IL121461A0 (de)
NO (1) NO973589L (de)
PL (1) PL321779A1 (de)
TR (1) TR199700794T1 (de)
WO (1) WO1997021439A1 (de)
ZA (1) ZA9610457B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763950B1 (fr) * 1997-06-02 2002-09-20 Esteve Labor Dr 2- {4- [4-(4,5-dichloro-2-methylimidazol-1-yl)butyl] -1- piperazinyl }-5-fluoropyrimidine, sa preparation et son utilisation therapeutique
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
US6046331A (en) * 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
DK1309591T3 (da) 2000-08-14 2007-03-26 Ortho Mcneil Pharm Inc Substituerede pyrazoler
AU8645401A (en) 2000-08-14 2002-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
EP1309592B9 (de) 2000-08-14 2007-02-28 Ortho-McNeil Pharmaceutical, Inc. Substituierte pyrazole
MXPA03001960A (es) 2000-09-06 2004-03-18 Johnson & Johnson Un metodo para tratar alergias.
US7795266B2 (en) 2003-09-25 2010-09-14 Helton David R Tetrahydroindolone derivatives for treament of neurological conditions
WO2005094827A1 (en) * 2004-03-30 2005-10-13 Kestrel Pharmaceuticals Inc. Methods for treating sexual dysfunction
BRPI0610258A2 (pt) 2005-04-26 2012-09-25 Hypnion Inc composto ou um sal farmaceuticamente eficaz do mesmo, composição farmacêutica, e, uso de um composto
PT1877390E (pt) 2005-04-26 2010-05-31 Hypnion Inc Compostos benzisoxazole-piridina e métodos para a sua utilização
GB2435827A (en) * 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted piperazine compounds for the treatment of food related disorders
CN115304590B (zh) * 2022-09-19 2024-05-28 皮摩尔新药(辽宁)有限公司 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9721439A1 *

Also Published As

Publication number Publication date
AU1376497A (en) 1997-07-03
CN1177297A (zh) 1998-03-25
AR004378A1 (es) 1998-11-04
TR199700794T1 (xx) 1997-11-21
ES2134709B1 (es) 2000-05-16
MX9706133A (es) 1997-11-29
IL121461A0 (en) 1998-02-08
HUP9800198A2 (hu) 1999-09-28
FR2742052A1 (fr) 1997-06-13
AU716665B2 (en) 2000-03-02
PL321779A1 (en) 1997-12-22
JPH11501051A (ja) 1999-01-26
NO973589D0 (no) 1997-08-04
ZA9610457B (en) 1997-06-24
FR2742052B1 (fr) 1998-04-10
NO973589L (no) 1997-10-08
CZ255197A3 (cs) 1998-01-14
CA2211161A1 (fr) 1997-06-19
ES2134709A1 (es) 1999-10-01
WO1997021439A1 (fr) 1997-06-19

Similar Documents

Publication Publication Date Title
EP1103243B1 (de) Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden
JPH05507731A (ja) 物質乱用障害の治療用医薬組成物
US20230059381A1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
HU202108B (en) Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
HU206042B (en) Process for producing pharmaceutical compositions comprising indole-3-carboxylic acid-endo-8-methyl-8-azabicyclo/3.2.1./oct-3-yl ester and/or 1,2,3-9-tetrahydro-9-methyl-3-(2-methyl-1h-imidazol-1-yl)-methyl-4h-carbazol-4-one, with an activity preventing or reducing opiate-, alcohol- and nicotine-dependence
EP0808166A1 (de) Arzneimittel zur behandlung von obsessiv-impulsiven erkrankungen wie schlafsapnoe, sexualfunktionsstörungen, erbrechen und reisekrankheit
CN1168441C (zh) 右旋美托咪定用于制备强化监护单位镇静药物的用途
JPH10507777A (ja) ドパミン系の障害を治療するためのフェノキシピペラジン誘導体
EP2034992A2 (de) Verfahren zur verbesserten harnausscheidung bei personen mit beeinträchtiger nierenfunktion
RU2254132C2 (ru) Способ подавления чувства страха
NO313935B1 (no) Anvendelse av angiotensin II antagonister for fremstilling av et medikamentfor behandling av svekket nerveledningshastighet, s¶rligdiabetisk nevropati
NZ543109A (en) Method of improved diuresis in individuals with impaired renal function
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
JP3598116B2 (ja) 遅発性ジスキネジアの治療用医薬組成物とその利用
NL8002041A (nl) Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel.
TWI289060B (en) Pharmaceutical composition for improving the recovery of post-stroke patients
US6221858B1 (en) Pyridyl-and pyrimidyl-piperazines in the treatment of substance abuse disorders
EP0642787A2 (de) Tabakentwöhnung
JP2003513888A (ja) 神経疾患治療用医薬品
WO1998005207A1 (en) Method for treating excessive aggression
CA2152280C (fr) Utilisation du riluzole comme radiorestaurateur
AU2006261296B2 (en) Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
EP1932529A1 (de) Verfahren zur verbesserten Harnausscheidung bei Personen mit beeinträchtiger Nierenfunktion
WO2000028984A1 (fr) Remedes agissant contre un trouble fonctionnel du tractus digestif

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19971117

17Q First examination report despatched

Effective date: 20000628

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001109